Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy
Jonathan Chou, David A. Quigley, Troy M. Robinson, et al.
Cancer Discovery (2020) Vol. 10, Iss. 3, pp. 351-370
Open Access | Times Cited: 234

Showing 26-50 of 234 citing articles:

CDK12 promotes tumorigenesis but induces vulnerability to therapies inhibiting folate one-carbon metabolism in breast cancer
Maria Grazia Filippone, Daniela Gaglio, R. Bonfanti, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 31
Isoginkgetin, a potential CDK6 inhibitor, suppresses SLC2A1/GLUT1 enhancer activity to induce AMPK-ULK1-mediated cytotoxic autophagy in hepatocellular carcinoma
Jie Yao, Shuming Tang, Chenyan Shi, et al.
Autophagy (2022) Vol. 19, Iss. 4, pp. 1221-1238
Open Access | Times Cited: 30
Mapping the landscape of genetic dependencies in chordoma
Tanaz Sharifnia, Mathias J. Wawer, Amy Goodale, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 19
CDK12/13 promote splicing of proximal introns by enhancing the interaction between RNA polymerase II and the splicing factor SF3B1
Valentina Panzeri, Marco Pieraccioli, Eleonora Cesari, et al.
Nucleic Acids Research (2023) Vol. 51, Iss. 11, pp. 5512-5526
Open Access | Times Cited: 16
Effects of super-enhancers in cancer metastasis: mechanisms and therapeutic targets
Shenglan Liu, Wei Dai, Bei Jin, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 7
A comprehensive insight on the recent development of Cyclic Dependent Kinase inhibitors as anticancer agents
Brilliant N. Marak, Jayanta Dowarah, Laldingluaia Khiangte, et al.
European Journal of Medicinal Chemistry (2020) Vol. 203, pp. 112571-112571
Closed Access | Times Cited: 41
Discovery of Potent and Selective CDK9 Degraders for Targeting Transcription Regulation in Triple-Negative Breast Cancer
Dan Wei, Hanlin Wang, Qinghe Zeng, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 19, pp. 14822-14847
Closed Access | Times Cited: 40
Oncogenic dysregulation of pre‐mRNA processing by protein kinases: challenges and therapeutic opportunities
Chiara Naro, Pamela Bielli, Claudio Sette
FEBS Journal (2021) Vol. 288, Iss. 21, pp. 6250-6272
Open Access | Times Cited: 36
Use of Circulating Tumor DNA for the Clinical Management of Metastatic Castration-Resistant Prostate Cancer: A Multicenter, Real-World Study
Baijun Dong, Liancheng Fan, Bin Yang, et al.
Journal of the National Comprehensive Cancer Network (2021) Vol. 19, Iss. 8, pp. 905-914
Closed Access | Times Cited: 34
Condensates induced by transcription inhibition localize active chromatin to nucleoli
Takaaki Yasuhara, Yu‐Hang Xing, Nicholas C. Bauer, et al.
Molecular Cell (2022) Vol. 82, Iss. 15, pp. 2738-2753.e6
Open Access | Times Cited: 27
FOXM1 Variant Contributes to Gefitinib Resistance via Activating Wnt/β-Catenin Signal Pathway in Patients with Non–Small Cell Lung Cancer
Shaoxing Guan, Xi Chen, Youhao Chen, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 17, pp. 3770-3784
Closed Access | Times Cited: 27
Expression pattern and prognostic significance of CDKs in breast cancer: An integrated bioinformatic study
Umar Mehraj, Shazia Sofi, Bader Alshehri, et al.
Cancer Biomarkers (2022) Vol. 34, Iss. 3, pp. 505-519
Closed Access | Times Cited: 23
Discovery of LL-K8-22: A Selective, Durable, and Small-Molecule Degrader of the CDK8-Cyclin C Complex
Mingyu Wang, Rongkun Lin, Jiacheng Li, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 7, pp. 4932-4951
Closed Access | Times Cited: 16
LncRNA EILA promotes CDK4/6 inhibitor resistance in breast cancer by stabilizing cyclin E1 protein
Zijie Cai, Qianfeng Shi, Yudong Li, et al.
Science Advances (2023) Vol. 9, Iss. 40
Open Access | Times Cited: 16
The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer
Theodora A. Constantin, Anabel Varela‐Carver, Kyle K. Greenland, et al.
British Journal of Cancer (2023) Vol. 128, Iss. 12, pp. 2326-2337
Open Access | Times Cited: 15
The CDK4/6 inhibitors biomarker landscape: The most relevant biomarkers of response or resistance for further research and potential clinical utility
Gabriele Antonarelli, Beatrice Taurelli Salimbeni, Antonio Marra, et al.
Critical Reviews in Oncology/Hematology (2023) Vol. 192, pp. 104148-104148
Closed Access | Times Cited: 15
Cyclin‐dependent kinases: Masters of the eukaryotic universe
Aleksandra J. Pluta, Cécilia Studniarek, Shona Murphy, et al.
Wiley Interdisciplinary Reviews - RNA (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 14
An Antiherpesviral Host-Directed Strategy Based on CDK7 Covalently Binding Drugs: Target-Selective, Picomolar-Dose, Cross-Virus Reactivity
DongHoon Yu, Sabrina Wagner, Martin Schütz, et al.
Pharmaceutics (2024) Vol. 16, Iss. 2, pp. 158-158
Open Access | Times Cited: 5
Therapeutic SHPRH-146aa encoded by circ-SHPRH dynamically upregulates P21 to inhibit CDKs in neuroblastoma
Saishuo Chang, Dong Ren, Li Zhang, et al.
Cancer Letters (2024) Vol. 598, pp. 217120-217120
Closed Access | Times Cited: 5
CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13
Jean C. Tien, Jie Luo, Yu Chang, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 10, pp. 101758-101758
Open Access | Times Cited: 5
Beyond Kinases: Targeting Replication Stress Proteins in Cancer Therapy
Katherine E. Baillie, Peter C. Stirling
Trends in cancer (2020) Vol. 7, Iss. 5, pp. 430-446
Closed Access | Times Cited: 38
The Promise and Current Status of CDK12/13 Inhibition for the Treatment of Cancer
Solomon Tadesse, Derek R. Duckett, Andrii Monastyrskyi
Future Medicinal Chemistry (2020) Vol. 13, Iss. 2, pp. 117-141
Closed Access | Times Cited: 37
Onconephrology: Update in Anticancer Drug-Related Nephrotoxicity
Clara García-Carro, Juliana Draibe, María José Soler
˜The œNephron journals/Nephron journals (2022) Vol. 147, Iss. 2, pp. 65-77
Open Access | Times Cited: 22
Brevilin A Isolated from Centipeda minima Induces Apoptosis in Human Gastric Cancer Cells via an Extrinsic Apoptotic Signaling Pathway
Dahae Lee, Hee Jae Kwak, Byoung Ha Kim, et al.
Plants (2022) Vol. 11, Iss. 13, pp. 1658-1658
Open Access | Times Cited: 20
CDK12 regulates co-transcriptional splicing and RNA turnover in human cells
Brian Magnuson, Karan Bedi, Ishwarya Venkata Narayanan, et al.
iScience (2022) Vol. 25, Iss. 9, pp. 105030-105030
Open Access | Times Cited: 20

Scroll to top